Clinical Experience Sample Clauses
Clinical Experience. Facility shall accept from University the mutually agreed upon number of students enrolled in the Program and shall provide the students with supervised clinical experience.
Clinical Experience. Claims for recent related clinical experience, if any, shall be made in writing by the nurse at the time of hiring on the application for employment form. The nurse shall co-operate with the Centre by providing verification of previous experience so that her recent related clinical experience may be determined and evaluated during her probationary period. Having established the recent related clinical experience, the Centre will credit a new nurse with one (1) annual service increment for each year of experience up to the maximum of the salary grid. If a period of more than two (2) years has elapsed since the nurse has occupied a full-time or part-time nursing position, then the number of increments to be paid, if any, shall be at the discretion of the Centre. All nurses currently employed shall be recognized for past experience, which was not recognized at the time of hire, up to the maximum salary grid.
Clinical Experience. Clinical Site shall accept from University the student and shall provide the student with supervised clinical experience, meeting the ASHA requirements and any state licensure laws, as applicable.
Clinical Experience. Clinical Site shall accept from University the student and shall provide the student with supervised clinical experience, meeting the BOP requirement and any state licensure laws, as applicable.
Clinical Experience. AFFILIATE shall provide the clinical experience for the students in UCLA EXTENSION’s Program (“Student(s)”) at the AFFILIATE facilities as set forth in this Agreement, at the dates and times only as mutually agreed to by the parties.
Clinical Experience. Agency shall accept from University the mutually agreed upon number of students enrolled in the Program and shall provide the students with supervised clinical experience.
Clinical Experience. I am familiar and in adherence with the Pedorthic Code of Ethics and regulatory statutes in all aspects of practice. I am confident in all interactions with clients. I have an understanding of my role in interactions with other agencies such as third-party insurance companies. I have observed office organization and management. I have observed office bookkeeping and billing procedures. I have demonstrated an ability to draft concise, timely and accurate records. I have participated in patient education. I have conducted and demonstrated the following examination techniques: - gait analysis - open kinetic chain - closed kinetic chain I have observed and Conducted assessment of at least 10 different client conditions: over-use injuries, systemic (e.g. arthritis, diabetes), geriatric, paediatric, neurological (e.g. MS, CMT), post-op, trauma, congenital I have engaged the client in the process of selecting from among treatment options, establishing desired outcomes and determining time frames; synthesize client goals and consider these when setting priority outcomes; review and evaluate with the client the range of resources and treatments available. I have successfully demonstrated the following during an assessment: - selection of appropriate treatment solution - rationale for selection - communicating a plan for client follow-up and answering any client questions and concerns related to client follow-up, under supervision I have demonstrated the ability to differentiate between the need for custom versus off-the- shelf orthotic. I have developed an understanding of inventory management. I have assisted the fitting of footwear, with specific attention to fit (size, shape, and volume) and function (appropriate style of shoe). I have carried out appropriate shoe selection and fitting following assessment of a variety of different client conditions/foot types. I have demonstrated awareness of and adherence to the safety procedures of the practicum site. I have demonstrated regular and proper use of personal safety equipment (Safety glasses, dust mask, etc.). I have demonstrated and adhere to proper handling of materials in the workplace. I have demonstrated and adhere to safe and proper use of machinery and tools in the workplace. I have demonstrated safe work ethic around co-workers. Following assessment and selection of appropriate orthotic solution, I have produced the following: Shoe modifications: - rocker - upper mods - lift extension - Buttress Cast modi...
Clinical Experience. Combination treatment with TSR-042 and niraparib is currently being assessed in ongoing Study 0000-00-000 (NCT03307785); no clinical data are currently available for TSR-042 and niraparib combination treatment. Niraparib is also being evaluated in combination with another anti-PD-1 agent, pembrolizumab, in patients with triple-negative breast cancer (TNBC) or recurrent PROC as part of a Phase 1/2 study (XXXXXXX/KEYNOTE-162).21 In Phase 1 of the study, 5 patients with TNBC and 9 patients with recurrent PROC received 200 mg pembrolizumab via IV infusion on Day 1 of each 21-day cycle and 200 mg (Dose Level 1) or 300 mg (Dose Level 2) niraparib per day orally. DLTs included neutropenia, anemia, and thrombocytopenia in 1 patient at Dose Level 1 and thrombocytopenia in 2 patients at Dose Level 2. The recommended Phase 2 dose regimen was determined to be 200 mg niraparib per day orally (increasing to 300 mg after Cycle 2 in patients with no significant hematologic toxicities) in combination with 200 mg pembrolizumab via IV infusion on Day 1 of each 21-day cycle. Tumor responses included partial response or complete response in 5 of the 9 patients with recurrent PROC; the remaining 4 patients had stable disease. In Phase 2 of the study as of August 2017, no new safety signals have been observed. In 36 patients with recurrent PROC, the most frequently reported Grade ≥3 TEAEs were anemia (16.7%), fatigue and platelet count decreased (5.6% each), and thrombocytopenia (2.8%).
Clinical Experience. Any arrangement between teacher education institutions and the Board which provides for clinical experiences in the District shall include consideration of the following:
1. Conferences between the student and the supervising teacher will occur prior to beginning the clinical experience.
2. Supervising teachers shall have tenure in the District.
3. Acceptance of a student for clinical experience shall be voluntary on behalf of the supervising teacher.
4. Students participating in clinical experiences shall not be used as substitute teachers.
5. The total amount of clinical experience honoraria will be placed in a common fund to be distributed pro rata among supervising teachers by June 30th of each school year.
6. Should the scope of student teaching herein defined as clinical experiences change beyond the present practice, those changes will be isolated and studied by a joint Association/Administration committee. The charge of that committee will be to reach agreement on any new procedures required by the changes.
Clinical Experience. TSR-042 has been evaluated as monotherapy in one Phase 1 study to date. Study 0000-00-000 (NCT02715284) is an ongoing first-in-human Phase 1 study of TSR-042 to evaluate the safety and tolerability, PK, pharmacodynamics, and clinical activity of TSR-042 in patients with advanced solid tumors. The study is being conducted in 2 parts: • Part 1 (dose escalation) of the study used a modified 3 + 3 design to evaluate 3 ascending weight-based doses of TSR-042 as follows: 1, 3, and 10 mg/kg administered every 2 weeks (Q2W) via IV infusion. • Part 2 of the study is being conducted in 2 subparts (Part 2A and Part 2B) to explore the safety and clinical activity of TSR-042 administered as a fixed dose (ie, not weight based). − In Part 2A, following the completion of Part 1, the safety and tolerability of TSR-042 was evaluated at fixed doses of 500 mg every 3 weeks (Q3W) and 1,000 mg every 6 weeks (Q6W) using a modified 6 + 6 design. − In Part 2B, the clinical activity, tolerability, and safety of TSR-042 at the recommended Phase 2 dose will be evaluated in patients with specific tumor types. As of 21 January 2018, 135 subjects with heavily pretreated advanced solid tumors have been treated with TSR-042 in Study 0000-00-000: 21 subjects in Part 1 and 114 subjects in Part 2A and 2B. The majority of these subjects (92.6%) reported at least 1 treatment-emergent adverse event (TEAE), with events of fatigue, nausea, and decreased appetite being the most frequently reported. Study drug-related TEAEs of Grade ≥ 3 were reported in 13 subjects (9.6%). The majority of these events occurred in only 1 subject each, with the exception of aspartate aminotransferase increased (3 subjects), alanine aminotransferase increased (2 subjects), and fatigue (2 subjects). Serious adverse events (SAEs) occurred in 38 subjects (28.1%), for 5 of these subjects the event was considered study drug-related. Eight subjects had an adverse event (AE) leading to study drug discontinuation. Six subjects had an AE leading to study drug discontinuation which was considered study drug-related. Three subjects had an AE leading to death. None of the AEs leading to death were considered to be related to the study drug. TSR-042 is also being studied in combination with other treatments, including TSR-022, an anti- TIM3 antibody (4020-01-001) and TSR-033, an anti-LAG3 antibody (4040-01-001). As of January 2018, 28 subjects received TSR-042 in combination with TSR-022 in Study 4020-01- 001.